Advanced

Long-Term Effects of GLP-1 Medications: What We Know So Far

GLP-1 Companion · 8 min read

As GLP-1 receptor agonists become one of the most widely prescribed medication classes in the world, understanding their long-term effects is more important than ever. The first GLP-1 medication, exenatide (Byetta), was approved in 2005, giving us nearly two decades of real-world data. Newer agents like semaglutide and tirzepatide have shorter track records but have been studied in some of the largest cardiovascular outcomes trials ever conducted. This article reviews what we know so far about the long-term effects, both beneficial and concerning.

Cardiovascular Benefits: The SELECT Trial

The landmark SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) was a randomized, double-blind, placebo-controlled trial of over 17,600 adults with overweight or obesity and established cardiovascular disease but without diabetes. The results, published in 2023, showed that semaglutide 2.4 mg (the Wegovy dose — not the lower 1 mg Ozempic dose) reduced the risk of major adverse cardiovascular events (MACE) by 20 percent (hazard ratio 0.80) compared to placebo, with a mean follow-up of nearly 40 months.

This finding was groundbreaking because it demonstrated cardiovascular benefit in patients without diabetes, establishing GLP-1 medications as more than just weight loss or diabetes drugs. The reduction in cardiovascular events included decreases in heart attack, stroke, and cardiovascular death. Importantly, statistical analyses suggest these benefits exceeded what weight loss alone could explain, pointing to direct anti-inflammatory and vascular protective mechanisms. Based on SELECT, Wegovy received FDA approval in March 2024 specifically for cardiovascular risk reduction — the first anti-obesity medication to carry this indication.

• The LEADER trial previously showed cardiovascular benefit of liraglutide in patients with type 2 diabetes.
• The SUSTAIN-6 trial demonstrated cardiovascular benefit of semaglutide in patients with type 2 diabetes.
• Anti-inflammatory effects of GLP-1 medications are believed to contribute to cardiovascular protection.
• Reductions in blood pressure, lipid levels, and inflammatory markers have been consistently observed.

Kidney Protection

The FLOW trial provided compelling evidence for kidney protection. This trial enrolled 3,533 patients who had both type 2 diabetes and chronic kidney disease — an important distinction, as these findings apply specifically to this high-risk combination, not to all patients on GLP-1 therapy. Using semaglutide 1.0 mg (the Ozempic dose), the trial was stopped early due to overwhelming efficacy. Results showed a 24 percent reduction in major kidney disease events (a composite endpoint including sustained decline in kidney function, need for dialysis, kidney transplant, or kidney-related death) compared to placebo.

The FLOW trial also demonstrated additional benefits beyond the kidney: an 18 percent reduction in cardiovascular events, 29 percent reduction in cardiovascular death, and 20 percent reduction in all-cause mortality. The renal benefits appear multifactorial — improved blood sugar control, lower blood pressure, reduced inflammation, and potentially direct effects on kidney tissue. For patients with diabetic kidney disease, GLP-1 medications are now considered an important additional tool alongside existing therapies like SGLT2 inhibitors and ACE inhibitors.

Thyroid Concerns: The C-Cell Question

All GLP-1 receptor agonists carry a boxed warning about the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). This warning is based on animal studies, primarily in rodents, where long-term exposure to GLP-1 receptor agonists caused dose-dependent increases in thyroid C-cell tumors.

However, the relevance of these findings to humans is uncertain. Rodent thyroid C-cells have a much higher density of GLP-1 receptors compared to human C-cells. In nearly two decades of human clinical use, no clear signal of increased medullary thyroid carcinoma has emerged in large pharmacovigilance databases or cardiovascular outcomes trials. Nonetheless, GLP-1 medications remain contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Pancreatitis Risk

Early concerns about an association between GLP-1 medications and pancreatitis were raised after post-marketing reports. Since then, multiple large-scale studies and meta-analyses have examined this question. The current evidence suggests that the absolute risk of pancreatitis with GLP-1 medications is very low, though a small increased relative risk compared to placebo cannot be entirely ruled out.

• The LEADER, SUSTAIN-6, and SELECT trials did not show a statistically significant increase in pancreatitis rates.
• Patients with a history of pancreatitis should discuss this risk with their provider before starting therapy.
• Symptoms of pancreatitis include severe, persistent abdominal pain that radiates to the back, often accompanied by nausea and vomiting.
• If pancreatitis is suspected, the medication should be stopped immediately and not restarted.

Bone Density

Rapid weight loss from any cause can lead to decreased bone mineral density, and GLP-1 medications are no exception. Studies have shown modest decreases in bone density during GLP-1-mediated weight loss, similar to what is seen with surgical weight loss. This is a particular concern for postmenopausal women and older adults who are already at elevated risk for osteoporosis and fractures.

However, the data on actual fracture risk is reassuring. Large clinical trials have not shown an increased rate of fractures in patients taking GLP-1 medications. Weight-bearing exercise and adequate calcium and vitamin D intake are recommended to support bone health during weight loss, regardless of the method used.

Gallbladder Issues

An increased risk of gallbladder-related events, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), has been consistently observed with GLP-1 medications. This risk is primarily driven by rapid weight loss rather than a direct drug effect, as gallstone formation increases whenever large amounts of fat are mobilized from storage.

• Clinical trials have reported gallbladder-related adverse events in approximately 1 to 3 percent of patients on GLP-1 therapy compared to 0.5 to 1 percent on placebo.
• The risk is higher at greater weight loss amounts and faster rates of weight loss.
• Symptoms include sudden, intense pain in the upper right abdomen, nausea, and vomiting after eating fatty foods.
• Patients with a history of gallbladder disease should discuss this risk with their provider.
• Gradual weight loss (one to two pounds per week) may help reduce gallstone risk, though this is difficult to control with medication.

Cancer Research

The relationship between GLP-1 medications and cancer risk is an area of active investigation. On the positive side, obesity is a well-established risk factor for multiple cancers, and weight loss achieved through GLP-1 therapy may reduce cancer risk over time. Some preclinical studies have even suggested direct anti-tumor effects of GLP-1 receptor activation in certain cancer types.

On the other hand, concerns have been raised about potential effects on specific cancer types, particularly pancreatic and thyroid cancers. Large-scale epidemiological analyses and long-term follow-up of clinical trial participants have not identified a clear increased risk of any cancer type with GLP-1 use, but continued surveillance is warranted given the expanding patient population and longer durations of use.

Gastrointestinal Effects Over Time

The most common side effects of GLP-1 medications are gastrointestinal: nausea, vomiting, diarrhea, and constipation. The good news from long-term data is that these side effects are predominantly transient. Most patients see significant improvement in GI symptoms within the first four to eight weeks at a stable dose. Slow dose titration, as recommended in prescribing guidelines, minimizes the severity and duration of these effects.

The risk-benefit profile of GLP-1 medications has become more favorable over time as more data accumulates. Cardiovascular and kidney benefits are increasingly well-documented, while most safety concerns from animal studies have not been borne out in human populations.

Long-Term Safety Data: The Big Picture

With nearly two decades of clinical use and some of the largest randomized controlled trials in metabolic medicine, GLP-1 medications have accumulated a robust safety profile. The cardiovascular and renal benefits are significant and appear to extend beyond what weight loss alone can explain. The most serious theoretical risks, particularly thyroid cancer and pancreatitis, have not materialized at meaningful rates in human studies. As with any medication, ongoing monitoring and pharmacovigilance remain important, especially as these drugs are prescribed to increasingly broad patient populations for longer durations.

Key Takeaways

• GLP-1 medications have demonstrated significant cardiovascular benefits, reducing major adverse cardiovascular events by 20 percent in the SELECT trial.
• Kidney protection is an emerging and important long-term benefit.
• Thyroid C-cell tumor risk seen in rodents has not been replicated in humans after nearly 20 years of clinical use.
• Pancreatitis risk is very low but warrants awareness and monitoring.
• Gallbladder events are modestly increased, primarily due to rapid weight loss rather than direct drug effects.
• Long-term cancer surveillance data is reassuring but ongoing.
• GI side effects are mostly transient and improve with continued use.
• The overall risk-benefit ratio strongly favors treatment for appropriate patients.

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Lincoff et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity. NEJM.